# Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia

> **NCT05266950** · PHASE1 · WITHDRAWN · sponsor: **Beijing Boren Hospital**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)

## Key facts

- **NCT ID:** NCT05266950
- **Lead sponsor:** Beijing Boren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-13
- **Primary completion:** 2023-12-12
- **Final completion:** 2023-12-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficulty in joining the group
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266950, "Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05266950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*